Recently, Bioeast Biotech announced the completion of the A+ round of financing of RMB 150 million. This round of financing was exclusively invested by LYFE CAPITAL.

After this round of financing, Bioeast Biotech will continue to increase investment in R&D and platform construction in the three major sectors of bioactive raw materials, nano-microspheres and protein purification fillers, vigorously introduce talents, rapidly deploy and expand overseas sales channels, and achieve the company's long-term goal of a world-renowned biopharmaceutical core raw material and overall solution service provider.

Bioeast Biotech was established in 2018, focusing on providing upstream core raw materials and overall solutions for biopharmaceutical customers. In the IVD raw material sector, Bioeast Biotech has established R&D and production platforms such as monoclonal (poly)clonal antibodies, original (eukaryotic) protein expression, protein purification, raw material evaluation and nanomaterials, providing customers with antigens, antibodies, biological enzymes, Quality control products, nano-microspheres and other core raw materials. In terms of IVD raw material evaluation, the company has built chemiluminescence, immunochromatography, immunoturbidimetric and molecular diagnostic evaluation platforms. It is one of the few companies in the world with multiple raw material evaluation platforms.